Can dehydroepiandrosterone sulfate (DHEA‑S) be elevated in a patient receiving estrogen and testosterone hormone replacement therapy?

DHEA-S and Hormone Replacement Therapy

DHEA-S levels typically decrease, not increase, when patients are on estrogen hormone replacement therapy. Testosterone replacement, however, can elevate DHEA-S levels depending on the formulation and metabolism.

Effect of Estrogen on DHEA-S

Estrogen replacement therapy consistently suppresses adrenal androgen production, leading to reduced DHEA-S levels:

• Oral estradiol (2 mg/day) decreases DHEA-S by approximately 23% (from 67.3 to 52.1 μg/dL) 1
• This suppression occurs even with minimal estradiol increases (as low as 6.5 pg/mL), demonstrating that adrenal function responds to very small changes in estrogen 2
• The mechanism involves decreased LH-driven ovarian stromal steroidogenesis and likely a direct adrenal suppressive effect of estrogen 1
• Both oral and transdermal estrogen formulations produce this effect 2

Effect of Testosterone on DHEA-S

The relationship between testosterone therapy and DHEA-S is more complex:

• Direct testosterone administration (transdermal or other formulations) increases serum testosterone levels but the effect on DHEA-S depends on the specific preparation 3
• DHEA supplementation (25-50 mg oral) increases both DHEA-S and downstream androgens including testosterone 4
• Testosterone therapy does not typically elevate DHEA-S unless the patient is receiving DHEA itself or a formulation that includes DHEA precursors 3

Clinical Algorithm for Interpretation

When evaluating elevated DHEA-S in a patient on hormone replacement:

1. If on estrogen alone: Elevated DHEA-S is unexpected and warrants investigation for:

   • Adrenal pathology (tumor if DHEA-S >600 μg/dL or 16,000 nmol/L) 5, 6
   • Non-compliance with estrogen therapy
   • Concomitant medications (glucocorticoid withdrawal, valproic acid) 5

2. If on testosterone alone: Mild elevation may occur depending on formulation, but marked elevation suggests:

   • Supraphysiologic dosing
   • Compounded preparations containing DHEA
   • Adrenal pathology requiring workup

3. If on combined estrogen-testosterone: The estrogen effect typically predominates, so DHEA-S should remain normal or decreased

Important Caveats

• Glucocorticoid use profoundly suppresses DHEA-S; withdrawal or dose reduction can cause rebound elevation 7, 8
• Oral contraceptives and other medications with estrogenic effects similarly suppress DHEA-S 6
• DHEA-S levels naturally decline with age (peak at 20-30 years), independent of menopause 4
• Sex hormone binding globulin (SHBG) increases 160% with oral estrogen, further reducing bioavailable androgens 1

Monitoring Recommendations

For patients on hormone replacement therapy 9:

• Measure baseline total testosterone and DHEA-S before starting therapy
• Recheck at 3-6 weeks after initiation
• Monitor every 6 months for signs of androgen excess or deficiency
• Aim for testosterone levels in the mid-normal physiologic premenopausal range
• DHEA-S should remain in the mid-normal range if DHEA supplementation is used 4

Bottom line: Estrogen suppresses DHEA-S. If DHEA-S is elevated despite estrogen therapy, investigate for adrenal pathology, medication non-compliance, or inappropriate testosterone/DHEA formulations. Standard testosterone replacement without DHEA should not significantly elevate DHEA-S.